Diego Benavent
Diego is a consultant rheumatologist at Hospital de Bellvitge, Barcelona. Aside from his activities regarding healthcare technology, his major interests are spondyloarthritis, patient-reported outcomes and musculoskeletal epidemiology. Diego the chair of the Newsletter Sub-Committee
| Poster 0519 | Sunday, 12.11.23 09.00 Spondyloarthritis Including Psoriatic Arthritis – Treatment: AxSpA Poster I Author: Deodhar, A (USA) Title: LONG-TERM SAFETY AND EFFICACY OF BIMEKIZUMAB IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: 5-YEAR RESULTS FROM A PHASE 2B STUDY AND ITS OPEN-LABEL EXTENSION  This 5-year open label extension trial showed that bimekizumab showed consistent safety and maintained its effectiveness in treating radiographic axial spondyloarthritis symptoms. |
| Oral 0777 | Sunday, 12.11.23 14.00 Spondyloarthritis Including Psoriatic Arthritis – Treatment II: PsA Author: Philippoteax, C (France) Title: CHARACTERISTICS OF DIFFICULT-TO-TREAT PSORIATIC ARTHRITIS: A COMPARATIVE ANALYSIS This study showed that difficult-to-treat (D2T) PsA is linked to increased axial involvement, structural damage, and therapy cessation due to skin poor dermatological control, while obesity and axial involvement are associated with very D2T PsA. |
| Poster 0520 | Sunday 12.11.23 09.00 Spondyloarthritis Including Psoriatic Arthritis – Treatment: AxSpA Poster I Author: Ramiro, S (The Netherlands) Title: HOW DO EARLY DISEASE ACTIVITY AND EARLY CLINICAL RESPONSE ASSOCIATE WITH LONG-TERM OUTCOMES WITH IXEKIZUMAB IN RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS? This post hoc analysis showed that among patients with r-axSpA treated with IXE, those achieving ASDAS CII or ASDAS < 2.1 at week 12 or 24 were more likely to reach the treatment goal of at least LDA by week 52. |
| Oral 1687 | Monday, 13.11.23 16.00 Spondyloarthritis Including Psoriatic Arthritis – Treatment II: PsA Author: Eder, L (Canada) Title: SEX OF THE PATIENT AFFECTS RESPONSE TO ADVANCED THERAPIES IN PSORIATIC ARTHRITIS: META-ANALYSIS OF DATA FROM RANDOMIZED CONTROLLED TRIALS This meta-analysis including 52 clinical trials showed that female patients participating in these studies were less likely to achieve efficacy end points for most classes of advanced therapies. |
| Poster 1417 | Monday, 13.11.23 09.00 Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster II: SpA Author: Pons, M (Denmark) Title: DO LONG-TERM PATIENT-REPORTED OUTCOMES IMPROVE SIMILARLY IN PSORIATIC ARTHRITIS AND AXIAL SPONDYLOARTHRITIS PATIENTS TREATED WITH SECUKINUMAB? RESULTS FROM THE EUROSPA COLLABORATION This collaborative study including 3062 axSpA patients and 3217 PsA patients showed similar effectiveness of secukinumab in axSpA and PsA based on PROs, yileding similar outcomes in pain, PGA, HAQ, and 24-month retention. |
| Poster 2236 | Tuesday, 14.11.23 09.00 Spondyloarthritis Including Psoriatic Arthritis – Treatment: SpA Poster III Author: Curtis, J (USA) Title: GUSELKUMAB PROVIDES RAPID CLINICALLY MEANINGFUL IMPROVEMENTS IN CLINICAL AND PATIENT REPORTED OUTCOMES AND SUSTAINED DISEASE CONTROL OF PSORIATIC ARTHRITIS Guselkumab led to clinically meaningful improvements compared to PBO, and achieving these improvements as early as week 4 was linked to better long-term disease control, emphasizing the significance of rapid early gains on prolonged patient outcomes. |